Asset profile
Rilvegostomig
Multispecific antibody
Phase 3underway
Evidence outlook · registrational
Non-Small Cell Lung Cancer: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2029-12-28.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
61 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 60 same-indication; 58 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Rilvegostomig: this drug | Phase 3 | Multispecific antibody | PD-1 and TIGIT | ||
| ZG005 | Phase 1/2 | Biologic (subtype unspecified) | PD-1 and TIGIT | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 | ||
| Brigatinib | Approved | Small molecule | ALK | ||
| Capmatinib | Approved | Small molecule | MET | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Ceritinib | Approved | Small molecule | ALK |
…and 46 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(32 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
October 2026 (1)
Phase 2Hepatocellular Carcinoma, Biliary Tract CancerActive not recruiting
Est. primary completion 2026-10-27 · NCT05775159 · CT.gov ↗
What to watch
2027 (10)
May 2027 (1)
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2027-05-04 · NCT04379596 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-30 · NCT04686305 · CT.gov ↗
What to watch
July 2027 (1)
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2027-07-19 · NCT07161414 · CT.gov ↗
What to watch
September 2027 (2)
October 2027 (1)
Phase 2Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer …Recruiting
Est. primary completion 2027-10-01 · NCT05489211 · CT.gov ↗
What to watch
November 2027 (2)
2028 (3)
March 2028 (1)
Phase 2Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant TherapyRecruiting
Est. primary completion 2028-03-01 · NCT07847710 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Biliary Tract CancerRecruiting
Est. primary completion 2028-06-12 · NCT06467357 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Stomach NeoplasmsRecruiting
Est. primary completion 2028-10-30 · NCT06630130 · CT.gov ↗
What to watch
2029 (10)
January 2029 (2)
February 2029 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-02-23 · NCT06996782 · CT.gov ↗
What to watch
April 2029 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-04-06 · NCT07098338 · CT.gov ↗
What to watch
Phase 3HER2-positive Gastric Cancer, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2029-04-27 · NCT06764875 · CT.gov ↗
What to watch
Phase 2Intrahepatic Cholangiocarcinoma (Icc)Not yet recruiting
Est. primary completion 2029-04-30 · NCT07128290 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Biliary Tract CancerRecruiting
Est. primary completion 2029-07-31 · NCT07221253 · CT.gov ↗
What to watch
August 2029 (1)
Phase 3Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal CancerRecruiting
Est. primary completion 2029-08-16 · NCT07431281 · CT.gov ↗
What to watch
October 2029 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-10-02 · NCT07115043 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-12-28 · NCT06357533 · CT.gov ↗
What to watch
2030 (7)
January 2030 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-01-17 · NCT06868277 · CT.gov ↗
What to watch
March 2030 (1)
Phase 3Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-03-15 · NCT06921785 · CT.gov ↗
What to watch
May 2030 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-05-28 · NCT05061550 · CT.gov ↗
What to watch
July 2030 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-07-01 · NCT06692738 · CT.gov ↗
What to watch
September 2030 (1)
Phase 3High-risk Muscle Invasive Urothelial CarcinomaRecruiting
Est. primary completion 2030-09-11 · NCT07720284 · CT.gov ↗
What to watch
November 2030 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-11-18 · NCT06627647 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Phase 1Solid TumorActive not recruiting
Est. primary completion 2031-12 · NCT04541108 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.